From the Cleveland Clinic
Recent therapeutic advances in metastatic renal cell carcinoma (RCC) have included agents targeted against vascular endothelial growth factor (VEGF).
A pioneering implantable artificial kidney developed jointly by teams of researchers at Cleveland Clinic, the University of California at San Francisco, and the University of Michigan in Ann Arbor is on track to meet project milestones in a pilot and feasibility study funded by the NIH.
The provision of in-hospital dialysis services over the next decade will necessitate a rethinking of the unit infrastructure.
Partial nephrectomy has been the procedure of choice for patients with poor renal function, tumors in solitary kidneys or bilateral renal tumors.
Considering the advancement in the diagnosis and treatment of glomerular disease, we formed a Glomerulonephritis Board (GN Board) at Cleveland Clinic that brings together key medical specialists.
The electronic medical record (EMR) has enabled creation of a CKD registry, a database that contains demographic information, clinical parameters, and outcome measurements of more than 41,000 CKD patients who have received medical care within the Cleveland Clinic Health System since January 2005.
There is sufficient evidence to demonstrate that lowering BP to less than 140/90 mm Hg offers cardiovascular and renal protection.
Prostate magnetic resonance (MR) provides high-resolution images of the prostate; seminal vesicles; and nearby pelvic organs and structures, including the bladder and rectum.
Data from 1,000 former kidney donors suggest that normal values of glomerular filtration rate decline with age.
Jihad Kaouk, MD, Director of the Center for Laparoscopic and Robotic Surgery, and his team performed the world's first completely transvaginal nephrectomy on March 13, 2009.
Last year, our lab team received a grant from the Flight Attendants Medical Research Institute (FAMRI). FAMRI was created from a settlement with tobacco companies over flight attendant exposure to secondhand smoke in their work.
A urethral sling placed via a transobturator approach has recently emerged as a treatment option for men with mild-to-moderate postprostatectomy incontinence.
About two years ago, having recognized that the prostate-specific antigen (PSA) cutoff level of 4.0 ng/mL did not always assist in accurately categorizing a man's risk for prostate cancer, we began to eliminate this—or any—artificial cutoff defining a "normal" PSA value.
Eric A. Klein, MD, a thought leader in the biology and management of prostate cancer, has been appointed chairman of the Glickman Urological & Kidney Institute.
The number of candidates on the list for kidney transplantation due to end-stage renal disease after a prior nonrenal transplant, particularly liver transplant, is growing significantly.
Sign Up for Free e-newsletters
- Optimal PSA Threshold For Targeted Biopsy Identified
- Plant-Based Phosphorus Best for Kidney Disease (CKD) Patients
- Testosterone Replacement Therapy (TRT) Beneficial in Diabetes Mellitus Patients
- Stopping Renal Cell Carcinoma (mRCC) Drugs Induces Tumor Flare
- Red Meat Contributes to Cardiovascular Disease (CVD) Risk Due to Gut Bacteria
- Once Pregnant, Living Kidney Donors More Likely to Have Hypertension
- Have malpractice award caps made any difference in medical practice?
- Erectile Dysfunction (ED) Linked to Early Vascular Disease
- Cost of Diabetes Care Continues to Rise
- 'Jekyll & Hyde' Molecule Could Lead to Aggressive Prostate Cancer (PCa)
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)